FY2025 Earnings Estimate for Cytokinetics Issued By B. Riley

Cytokinetics, Incorporated (NASDAQ:CYTK) – Analysts at B. Riley raised their FY2025 earnings estimates for Cytokinetics in a research note issued to investors on Monday, November 10th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn ($5.63) per share for the year, up from their prior estimate of ($5.72). B. Riley currently has a “Buy” rating and a $90.00 target price on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q4 2025 earnings at ($1.60) EPS, FY2026 earnings at ($6.47) EPS, FY2027 earnings at ($5.81) EPS, FY2028 earnings at ($3.52) EPS and FY2029 earnings at $0.41 EPS.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The business had revenue of $1.94 million during the quarter, compared to analysts’ expectations of $6.05 million. During the same quarter in the prior year, the firm earned ($1.36) earnings per share. Cytokinetics’s quarterly revenue was up 318.1% on a year-over-year basis.

Several other equities analysts also recently issued reports on the stock. Royal Bank Of Canada upped their price objective on shares of Cytokinetics from $82.00 to $87.00 and gave the company an “outperform” rating in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a report on Tuesday, October 21st. Stifel Nicolaus raised their price objective on Cytokinetics from $87.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Citigroup lifted their price objective on Cytokinetics from $77.00 to $84.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $72.00 target price on shares of Cytokinetics in a research report on Tuesday, September 2nd. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $77.86.

Cytokinetics Price Performance

Cytokinetics stock opened at $65.94 on Wednesday. The stock has a market capitalization of $8.06 billion, a P/E ratio of -12.93 and a beta of 0.58. Cytokinetics has a 12-month low of $29.31 and a 12-month high of $66.98. The firm’s 50-day moving average is $56.46 and its two-hundred day moving average is $42.63.

Institutional Trading of Cytokinetics

Several large investors have recently modified their holdings of the business. Gabelli Funds LLC grew its holdings in Cytokinetics by 313.3% during the 3rd quarter. Gabelli Funds LLC now owns 34,759 shares of the biopharmaceutical company’s stock worth $1,910,000 after acquiring an additional 26,349 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Cytokinetics during the third quarter worth about $2,060,000. Orion Porfolio Solutions LLC acquired a new position in Cytokinetics in the third quarter worth about $617,000. GW&K Investment Management LLC bought a new stake in Cytokinetics in the third quarter valued at about $9,930,000. Finally, Dimensional Fund Advisors LP raised its stake in Cytokinetics by 59.8% during the third quarter. Dimensional Fund Advisors LP now owns 51,259 shares of the biopharmaceutical company’s stock valued at $2,817,000 after buying an additional 19,173 shares in the last quarter.

Insider Buying and Selling

In other Cytokinetics news, Director Edward M. Md Kaye sold 6,757 shares of the stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $60.00, for a total value of $405,420.00. Following the completion of the sale, the director owned 9,778 shares of the company’s stock, valued at $586,680. This trade represents a 40.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Wendell Wierenga sold 4,375 shares of the business’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $58.68, for a total transaction of $256,725.00. Following the transaction, the director directly owned 32,444 shares in the company, valued at approximately $1,903,813.92. The trade was a 11.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 62,158 shares of company stock worth $3,502,145. Company insiders own 2.70% of the company’s stock.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.